Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 101–200 of 1,000
Challenges in natural product-based drug discovery assisted with in silico -based methods
Simoben, C. V., Babiaka, S. B., Moumbock, A. F. A., Namba-Nzanguim, C. T., Eni, D. B., Medina‐Franco, J. L., Günther, S., Ntie‐Kang, F., & Sippl, W. (2023) · RSC Advances · doi:10.1039/d3ra06831e · Cited by 87
Kuo, H. D., Wu, R., Li, S. N., Yang, Y., & Kong, A. T. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0355-5 · Cited by 82
Chatterjee, B., Ghosh, K. K., & Kanade, S. R. (2019) · BioFactors · doi:10.1002/biof.1544 · Cited by 83
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
Huang, M., Zhang, J., Yan, C., Li, X., Zhang, J., & Ling, R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103184 · Cited by 77
The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
Martinsen, J. T., Gunst, J. D., Højen, J. F., Tolstrup, M., & Søgaard, O. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01112 · Cited by 88
“This suggested a moderate latency reversing effect ofMGN1703, but no reduction was observed in the proviral reservoir size assessed by total and integrated HIV-1 DNA in CD4+ T cells.”
BackgroundInfluentialScholz, B., Schulte, J. S., Hamer, S., Himmler, K., Pluteanu, F., Seidl, M. D., Stein, J., Wardelmann, E., Hammer, E., Völker, U., et al. (2019) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.118.007071 · Cited by 83
TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression
Jones, D. L., Haak, A. J., Caporarello, N., Choi, K. M., Ye, Z., Yan, H., Varelas, X., Ordog, T., Ligresti, G., & Tschumperlin, D. J. (2019) · Journal of Cell Science · doi:10.1242/jcs.233486 · Cited by 77
Current paradigms in epigenetic anticancer therapeutics and future challenges
Singh, M. P., Kumar, V., Sehrawat, N., Yadav, M. K., Chaudhary, M., Upadhyay, S. K., Kumar, S., Sharma, V., Kumar, S., Dilbaghi, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.013 · Cited by 86
Li, C., Wang, Y., Gong, Y., Zhang, T., Huang, J., Tan, Z. W., & Xue, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01045-1 · Cited by 84
“HDAC inhibitors (HDACi) induce cancer cell cycle arrest, differentiation, and death; reduce angiogenesis; and modulate immune responses [76].”
BackgroundMicrotubule associated proteins as targets for anticancer drug development
Khwaja, S., Kumar, K., Das, R., & Negi, A. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105320 · Cited by 82
HDAC1/2/3 are major histone desuccinylases critical for promoter desuccinylation
Li, J., Lu, L., Liu, L., Ren, X., Chen, J., Yin, X., Xiao, Y., Li, J., Wei, G., Huang, H., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00573-9 · Cited by 85
“The ability to elevate histone succinylation is not unique to TSA, because treatment with two other HDAC inhibitors, SAHA and sodium butyrate 35 , also increased histone succinylation to a similar extent to that of TSA (Fig.”
BackgroundAdhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 74
Histone Deacetylase Inhibitors and Diabetic Kidney Disease
Hadden, M. J., & Advani, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092630 · Cited by 83
The role of altered protein acetylation in neurodegenerative disease
Kabir, F., Atkinson, R., Cook, A. L., Phipps, A. J., & King, A. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1025473 · Cited by 75
“Additionally, both pan-HDACi belinostat and panobinostat have been used to treat cutaneous T-cell lymphoma and myeloma (Eckschlager et al., 2017).”
BackgroundEpigenetic inhibitors target multiple stages of Plasmodium falciparum parasites
Coetzee, N., von Grüning, H., Opperman, D., van der Watt, M., Reader, J., & Birkholtz, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-59298-4 · Cited by 83
Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug
Kopytko, P., Piotrowska, K., Janisiak, J., & Tarnowski, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062828 · Cited by 74
“The enzymes that play a key role in the acetylation process are histone acetyltransferases (HATs), otherwise known as K-acetyltransferases (KATs) [7,8].”
BackgroundHepatic Osteodystrophy—Molecular Mechanisms Proposed to Favor Its Development
Ehnert, S., Aspera-Werz, R. H., Ruoß, M., Dooley, S., Hengstler, J. G., Nadalin, S., Relja, B., Badke, A., & Nussler, A. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102555 · Cited by 72
H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
Hałasa, M., Wawruszak, A., Przybyszewska-Podstawka, A., Jaruga, A., Guz, M., Kałafut, J., Stepulak, A., & Cybulski, M. (2019) · Cells · doi:10.3390/cells8050485 · Cited by 84
“HDIs have been classified into five basic groups: hydroxamic acids (vorinostat, belinostat, panobinostat, givinostat, resminostat, abexinostat, quisinostat, rocilinostat, and practinostat), short chain fatty acids (valproic acid, butyric acid, and phenylbutyric acid), benzamides (entinostat, mocetinostat, tacedinaline…”
BackgroundGao, Y., Zhang, H., Lirussi, F., Garrido, C., Ye, X., & Xie, T. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114224 · Cited by 73
Man, K., Brunet, M. Y., Fernández‐Rhodes, M., Williams, S., Heaney, L. M., Gethings, L. A., Federici, A., Davies, O. G., Hoey, D. A., & Cox, S. C. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12118 · Cited by 79
“HDAC inhibitors (HDACis) are small molecular compounds that have been extensive explored to reprogram the epigenome for cancer therapeutics and regenerativemedicine applications (Bolden et al., 2013; Eckschlager et al., 2017; Marks, 2010).”
BackgroundSteering the antitumor drug discovery campaign towards structurally diverse indolines
Thakur, A., Singh, A., Kaur, N., Ojha, R., & Nepali, K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103436 · Cited by 72
Semaan, J., El-Hakim, S., Ibrahim, J.-N., Safi, R., Elnar, A. A., & Boustany, C. E. (2020) · Breast Cancer · doi:10.1007/s12282-020-01063-6 · Cited by 73
Explainable drug sensitivity prediction through cancer pathway enrichment
Tang, Y.-C., & Gottlieb, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-82612-7 · Cited by 90
Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Barcena-Varela, M., Colyn, L., & Fernandez-Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 72
“They are currently licensed for the treatment of different malignancies and are being explored as therapies for many other tumors [90].”
BackgroundThe “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”
Strub, T., Ballotti, R., & Bertolotto, C. (2020) · Theranostics · doi:10.7150/thno.36218 · Cited by 77
“Several groups have previously reported the effect of pan‐HDACi on tumor cells in a variety of cancers [48,49].”
BackgroundHuang, M., Huang, J., Zheng, Y., & Sun, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.078 · Cited by 67
Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma
Pant, K., Peixoto, E., Richard, S., & Gradilone, S. A. (2020) · Cells · doi:10.3390/cells9030780 · Cited by 76
“HDAC6-mediated deacetylation of α-tubulin disrupts the stability of the axoneme leading to ciliary loss [7,10].”
BackgroundAnticancer properties of chimeric HDAC and kinase inhibitors
Biersack, B., Polat, S., & Höpfner, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.005 · Cited by 77
Peng, X., Li, L., Chen, J., Ren, Y., Liu, J., Yu, Z., Cao, H., & Chen, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01863 · Cited by 70
Ciaffaglione, V., Modica, M. N., Pittalà, V., Romeo, G., Salerno, L., & Intagliata, S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100473 · Cited by 78
Patra, S., Praharaj, P. P., Klionsky, D. J., & Bhutia, S. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.004 · Cited by 71
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 71
“Chemically, HDACi can be classified according to their ZBG (Table 2): aliphatic (shortchain fatty) acids; hydroxamic acids; ortho-aminoanilides, also called benzamides; thiols and cyclic peptides [55,69].”
BackgroundPROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 77
Chen, J., Li, N., Liu, B., Ling, J., Yang, W., Pang, X., & Li, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117469 · Cited by 68
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
Bartolucci, D., Montemurro, L., Raieli, S., Lampis, S., Pession, A., Hrelia, P., & Tonelli, R. (2022) · Cancers · doi:10.3390/cancers14184421 · Cited by 74
Is euchromatin really open in the cell?
Maeshima, K., Iida, S., Shimazoe, M. A., Tamura, S., & Ide, S. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.05.007 · Cited by 74
Shen, Y. L., Chen, J.-Q., & Li, X. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101374 · Cited by 96
“156 Currently, HDAC inhibitors such as vorinostat, romidepsin, belinostat, and panobino-stat have received FDA approval for marketing, primarily for lymphomas and myelomas.”
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
Shah, R. R., & Stonier, P. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12759 · Cited by 68
Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting
Zong, X., & Nephew, K. P. (2019) · Cancers · doi:10.3390/cancers11070934 · Cited by 69
Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Pojani, E., & Barlocco, D. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200203113926 · Cited by 69
Wang, C., Zhou, Z., Subhramanyam, C. S., Cao, Q., Heng, Z. S., Liu, W., Fu, X., & Hu, Q. (2020) · Communications Biology · doi:10.1038/s42003-020-0983-4 · Cited by 71
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 72
“In addition, Class I HDACs contribute to adenocarcinoma metastasis through the induction of EMT via loss of E-cadherin expression due to epigenetic silencing by a transcriptional repressor complex containing the TF Snail (zinc finger protein SNAI1) acting in concert with HDAC1 and HDAC2 [197].”
BackgroundInfluentialMartin, M. W., Lee, J. Y., Lancia, D. R., Ng, P. Y., Han, B., Thomason, J. R., Lynes, M. S., Marshall, C. G., Conti, C., Collis, A., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.021 · Cited by 58
De, U., Son, J. Y., Sachan, R., Park, Y. J., Kang, D., Yoon, K., Lee, B. M., Kim, I. S., Moon, H. R., & Kim, H. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092743 · Cited by 63
“Previous studies have shown that the SIRT inhibitors induce apoptosis through several mechanisms in a variety of cancer cells [21,22].”
BackgroundEpigenetic Reprogramming of TGF-β Signaling in Breast Cancer
Suriyamurthy, S., Baker, D. A., ten Dijke, P., & Iyengar, P. V. (2019) · Cancers · doi:10.3390/cancers11050726 · Cited by 69
Noonepalle, S. K. R., Shen, S., Ptáček, J., Tavares, M. T., Zhang, G., Stránský, J., Pavlíček, J., Ferreira, G. M., Hadley, M. M., Pelaez, G. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00567 · Cited by 64
The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
Dewanjee, S., Vallamkondu, J., Kalra, R. S., Chakraborty, P., Gangopadhyay, M., Sahu, R., Medala, V. K., John, A. A., Reddy, P. H., Feo, V. D., et al. (2021) · Cells · doi:10.3390/cells10061340 · Cited by 72
“In contrast, SIRT inhibitors comprise entirely different mechanisms of action [38,39].”
BackgroundGao, Y., Duan, J., Dang, X., Yuan, Y., Wang, Y., He, X., Bai, R., Ye, X., & Xie, T. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2195991 · Cited by 66
Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach
Sixto‐López, Y., Bello, M., & Correa‐Basurto, J. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00304-2 · Cited by 70
“Among these HDACis, those containing hydroxamic acid are the most examined and potent [9].”
BackgroundNovel targeted therapies of T cell lymphomas
Iżykowska, K., Rassek, K., Korsak, D., & Przybylski, G. K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01006-w · Cited by 65
“They remove the acetyl group from histones and, as a result, modulate the chromatin structure and change the accessibility of transcription factors to their target DNA sequence [2].”
BackgroundRevisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
“Considering the limited therapeutic effect of HDACis as monotherapy in several solid tumors, the majority of current trials are focused on the synergistic effects of HDACis in combination with other anti-cancer agents/drugs, or radiotherapy protocols [254,256].”
BackgroundVascular toxicity associated with anti-angiogenic drugs
Neves, K. B., Montezano, A. C. I., Lang, N. N., & Touyz, R. M. (2020) · Clinical Science · doi:10.1042/cs20200308 · Cited by 64
Osipyan, A., Chen, D., & Dekker, F. J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.012 · Cited by 65
Karaźniewicz‐Łada, M., Główka, A. K., Mikulska, A. A., & Główka, F. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179582 · Cited by 63
“(HDAC) inhibitor [176] The latter mechanism is responsible for the VPA anticancer potential to alter the expression of many genes, including tumor suppressor genes [177].”
BackgroundTargeting bromodomain and extraterminal proteins in breast cancer
Sahni, J. M., & Keri, R. A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.015 · Cited by 64
Korfei, M., Stelmaszek, D., MacKenzie, B., Skwarna, S., Chillappagari, S., Bach, A., Ruppert, C., Saito, S., Mahavadi, P., Klepetko, W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207915 · Cited by 64
“LBH589 is an orally available, novel hydroxamic acid pan-HDAC inhibitor that potently inhibits all class I, -II and IV HDAC enzymes at low nanomolar concentrations [34,38,39], and is reported to be at least 10-fold more potent than SAHA [61].”
BackgroundInfluentialYe, J., Zha, J., Shi, Y., Li, Y., Yuan, D., Chen, Q., Lin, F., Fang, Z., Yu, Y., Dai, Y., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0723-0 · Cited by 61
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Frühauf, A., & Meyer‐Almes, F. (2021) · Molecules · doi:10.3390/molecules26175151 · Cited by 63
He, Y., Fang, Y., Zhang, M., Zhao, Y., Tu, B., Shi, M., Muhitdinov, B. I., Asrorov, A. M., Xu, Q., & Huang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.022 · Cited by 60
Galow, A.-M., & Peleg, S. (2022) · Cells · doi:10.3390/cells11030468 · Cited by 66
Pu, J., Liu, T., Wang, X., Sharma, A., Schmidt‐Wolf, I. G. H., Jiang, L., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00507-5 · Cited by 69
Pharmacological targeting of the cancer epigenome
Mabe, N. W., Perry, J. A., Malone, C. F., & Stegmaier, K. (2024) · Nature Cancer · doi:10.1038/s43018-024-00777-2 · Cited by 77
“The therapeutic efficacy of HDAC inhibitors is likely mediated by inhibition of class I HDACs (HDAC1–3,8), although the specificity for individual HDAC members varies between small molecules, and off-target effects may partially mediate additional therapeutic effects 16,17 .”
Patra, S., Panigrahi, D. P., Praharaj, P. P., Bhol, C. S., Mahapatra, K. K., Mishra, S. R., Behera, B. P., Jena, M., & Bhutia, S. K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03098-1 · Cited by 63
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression
Cao, N., Yu, Y., Zhu, H., Chen, M., Chen, P., Zhuo, M., Mao, Y., Li, L., Zhao, Q., Wu, M., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2561-6 · Cited by 64
Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies
Gatzka, M. (2018) · Cancers · doi:10.3390/cancers10060155 · Cited by 61
“In addition, histone-independent actions of HDACi, in particular the hyperacetylation of tumor suppressor p53, chaperone HSP90, and NF-κB subunit p65/RelA, may contribute to their effects on drug-resistant tumor cells and reflect the broad impact of HDAC/i on cancer in general [48].”
BackgroundThe role of endogenous retroviruses‐K in human cancer
Salavatiha, Z., Soleimani‐Jelodar, R., & Jalilvand, S. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2142 · Cited by 60
“It could also enhance the response to other therapies.(143) As a new promising treatment 8 of 13 SALAVATIHA ET AL.”
BackgroundCRISPR/Cas mediated epigenome editing for cancer therapy
Ansari, I., Chaturvedi, A., Chitkara, D., & Singh, S. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.018 · Cited by 62
Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer
Levit, S. L., & Tang, C. (2021) · Nanomaterials · doi:10.3390/nano11041048 · Cited by 61
“Inhibitors of these targets can arrest tumor growth and induce apoptosis [63].”
BackgroundTang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12546 · Cited by 66
“This may be the epigenetic mechanism for Histone deacetylase inhibitors as anticancer drugs [166] 2017 Treg cell: Inhibition of HDAC6 activates naive T cells, while class II HDAC inhibitors enhance Treg number and function.”
BackgroundEpigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
Autin, P., Blanquart, C., & Fradin, D. (2019) · Cancers · doi:10.3390/cancers11101530 · Cited by 62
“Here, we will present only the major pathways affected by HDACi (fo more details, see reviews [36,37]).”
BackgroundBou‐Fakhredin, R., Franceschi, L. D., Motta, I., Cappellini, M. D., & Taher, A. T. (2022) · Pharmaceuticals · doi:10.3390/ph15060753 · Cited by 64
“Vorinostat (also known as suberoylanilide hydroxamic acid or SAHA) is a hydroxamic acid group pan-HDAC inhibitor that has been used in many research studies including cancer treatment [72].”
BackgroundHDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer
Deng, R., Zhang, P., Liu, W., Zeng, X., Ma, X., Shi, L., Wang, T., Yin, Y., Chang, W., Zhang, P., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0589-6 · Cited by 56
“Of our interest, HDAC is a potential target of therapy in many cancers, and certain HDAC inhibitors (HDACIs) have been applied clinically [23].”
BackgroundBandolik, J. J., Hamacher, A., Schrenk, C., Weishaupt, R., & Kassack, M. U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123052 · Cited by 57
“It is well known that epigenetic modifications such as histone acetylation or DNA methylation are dysregulated in cancer and moreover in chemoresistance development [15,16].”
Beyond genetics: Exploring the role of epigenetic alterations in breast cancer
Prabhu, K. S., Sadida, H. Q., Kuttikrishnan, S., Junejo, K., Bhat, A. A., & Shahab Uddin, M. S. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155174 · Cited by 63
Reßing, N., Sönnichsen, M., Osko, J. D., Schöler, A., Schliehe‐Diecks, J., Skerhut, A. J., Borkhardt, A., Hauer, J., Kassack, M. U., Christianson, D. W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01888 · Cited by 56
Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091883 · Cited by 51
“Further serious limitations of the HDACi SAHA and FK228 include a lack of efficacy in solid tumors combined with high prevalence of drug-induced side effects such as cardiotoxicity [96,97].”
BackgroundAl-Sanea, M. M., Gotina, L., Mohamed, M. F. A., Parambi, D. G. T., Anwar, H., Mathew, B., Youssif, B. G. M., Alharbi, K. S., Elsayed, Z. M., Abdelgawad, M. A., et al. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s237957 · Cited by 56
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Dhuguru, J., & Ghoneim, O. (2022) · Molecules · doi:10.3390/molecules27072294 · Cited by 58
Immunotherapies targeting stimulatory pathways and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01085-3 · Cited by 52
Johnson, R. W., & Suva, L. J. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0362-4 · Cited by 59
“There are currently four HDAC inhibitors that are FDA-approved, and many others that are currently in phase I–III clinical trials, for the treatment of other tumor types and diseases, including chronic treatment of epilepsy and migraines [95].”
Shen, F., Boccuto, L., Pauly, R., Srikanth, S., & Chandrasekaran, S. (2019) · Genome biology · doi:10.1186/s13059-019-1661-z · Cited by 58
“KDAC inhibitors block distinct histone deacetylases resulting in transcriptomic changes that influence the levels of metabolic enzymes [48, 53].”
Repurposing Vorinostat for the Treatment of Disorders Affecting Brain
Athira, K. V., Sadanandan, P., & Chakravarty, S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08660-4 · Cited by 59
“While most of these are pan-HDAC inhibitors, newer HDAC inhibitors are selective and include rocilinostat (ACY1215)— inhibits class II HDAC, CHR-3996—inhibits class I HDAC, and ACY-738 and ACY-775—both inhibit HDAC6 (Eckschlager et al., 2017; Jochems et al., 2014).”
BackgroundEpigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
Fernandez, A., O’Leary, C. G., O'Byrne, K. J., Burgess, J. T., Richard, D. J., & Suraweera, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.685440 · Cited by 57
Schäker‐Hübner, L., Warstat, R., Ahlert, H., Mishra, P., Kraft, F. B., Schliehe‐Diecks, J., Schöler, A., Borkhardt, A., Breit, B., Bhatia, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01119 · Cited by 51
Overview on Biological Activities of Imidazole Derivatives
Gujjarappa, R., Kabi, A. K., Sravani, S., Garg, A., Vodnala, N., Tyagi, U., Kaldhi, D., Ravichandiran, V., Singh, V., Gupta, S., et al. (2022) · Materials horizons · doi:10.1007/978-981-16-8399-2_6 · Cited by 61
Epigenetic regulators of programmed death-ligand 1 expression in human cancers
Kumar, S., & Sharawat, S. K. (2018) · Translational research · doi:10.1016/j.trsl.2018.05.011 · Cited by 57
Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival
Foggetti, G., Ottaggio, L., Russo, D., Mazzitelli, C., Monti, P., Degan, P., Miele, M., Fronza, G., & Menichini, P. (2019) · Bioscience Reports · doi:10.1042/bsr20181345 · Cited by 50
“Interestingly, several clinical trials using SAHA or other HDACi are in progress in different types of tumors [56,57].”
HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
Spreafico, M., Gruszka, A., Valli, D., Mazzola, M., Deflorian, G., Quintè, A., Totaro, M. G., Battaglia, C., Alcalay, M., Marozzi, A., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00844 · Cited by 54
“Histone deacetylase inhibitors (HDACi) possess an anticancer activity through the induction of apoptosis and cell cycle arrest (Eckschlager et al., 2017) in solid and hematological tumors (Ceccacci and Minucci, 2016; Imai et al.”
BackgroundDevelopment of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
Toutah, K., Nawar, N., Timonen, S., Sorger, H., Raouf, Y. S., Bukhari, S., von Jan, J., Ianevski, A., Gawel, J. M., Olaoye, O. O., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00420 · Cited by 51
El‐Shehawy, A. A., Elmetwalli, A., El‐Far, A. H., Mosallam, S. A. E.-R., Salama, A. F., Babalghith, A. O., Mahmoud, M. A., Mohany, H., Gaber, M., & El-Sewedy, T. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03872-6 · Cited by 56
“HDAC inhibitors lead to increased histone acetylation and transcriptional upregulation of gene expression, inducing cancer cell cycle arrest, apoptosis, and necrosis in a variety of transformed cell lines by several mechanisms depending on the cancer type; HDAC inhibitors, and doses [79].”
BackgroundEpigenetic Targets and their Inhibitors in Cancer Therapy
Zhao, L., Duan, Y., Lü, P., Zhang, Z., Zheng, X., Wang, J., & Feng, W. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181224095449 · Cited by 55
Histone Deacetylases in Kidney Physiology and Acute Kidney Injury
Hyndman, K. A. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2020.01.005 · Cited by 53
Colorectal Cancer and Probiotics: Are Bugs Really Drugs?
Lamichhane, P., Maiolini, M., Alnafoosi, O., Hussein, S., Alnafoosi, H., Umbela, S., Richardson, T., Alla, N., Lamichhane, N., Subhadra, B., et al. (2020) · Cancers · doi:10.3390/cancers12051162 · Cited by 50
Novel treatments for autism spectrum disorder based on genomics and systems biology
Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 55
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target
Cheng, C., Yang, J., Li, S.-W., Huang, G., Li, C., Min, W.-P., & Sang, Y. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03417-0 · Cited by 49
Sun, P., Wang, J., Khan, K. S., Yang, W., Ng, W., Ilment, N. V., Zessin, M., Bülbül, E. F., Robaa, D., Erdmann, F., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01132 · Cited by 51
Lactylation in cancer: metabolic mechanism and therapeutic strategies
Sui, Y., Shen, Z., Wang, Z., Feng, J., & Zhou, G. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02349-4 · Cited by 61
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Okubo, K., Isono, M., Miyai, K., Asano, T., & Sato, A. (2020) · Cancer Science · doi:10.1111/cas.14225 · Cited by 49
Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
Moody, R., Wilson, K., Jaworowski, A., & Plebanski, M. (2020) · Cancers · doi:10.3390/cancers12030673 · Cited by 57
Aparicio-Blanco, J., Sanz-Arriazu, L., Lorenzoni, R., & Blanco‐Prieto, M. J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119283 · Cited by 54
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
